Correlation of Increased Vascular Endothelial Growth Factor With Neovascularization and Permeability in Ischemic Central Vein Occlusion.

Boyd, S R; Zachary, I; Chakravarthy, Usha; Allen, George J.; Wisdom, G. Brian; Cree, I A; Martin, J. F.; Hykin, Phil

doi:10.1097/00006982-200306000-00038

Cited by 50 publications

(68 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…14 The level of VEGF expression in the aqueous humor is closely correlated to the extent of neovascularization, and inhibition of VEGF through intravitreal injection of anti-VEGF monoclonal antibodies in adult non-human primate eyes was found to prevent NVI associated with retinal ischemia. 14,15 Bevacizumab is an anti-VEGF recombinant humanized monoclonal antibody that has been approved by the US Food and Drug Administration (FDA) for the treatment of certain forms of cancer such as metastatic colorectal cancer. 16 Although intravitreal injection of bevacizumab has not received FDA approval, bevacizumab has been widely used off-label to treat VEGF-mediated ocular conditions such as choroidal neovascularization secondary to age-related macular degeneration, diabetic macular edema, CRVO-associated macular edema and as an adjunctive agent in glaucoma surgery.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

Olmos

Sayed

Moraczewski

et al. 2015

Eye

View full text Add to dashboard Cite

Aims To compare the outcomes of neovascular glaucoma (NVG) treated with and without intravitreal bevacizumab in a large case comparison study. Methods The study is a retrospective, comparative, case series of 163 eyes of 151 patients with NVG, including 99 treated without and 64 treated with intravitreal bevacizumab. Medical and surgical treatments for NVG were assessed. The main outcome measures were visual acuity (VA) and intraocular pressure (IOP).Results At the time of NVG diagnosis, the median VA was count fingers (CF) in the non-bevacizumab group and 2/300 in the bevacizumab group. IOP (mean ± SD) was 43.1 ± 13.0 mm Hg in the non-bevacizumab group and 40.8 ± 11.5 mm Hg in the bevacizumab group. IOP (mean ± SD) decreased to 18.3 ± 13.8 mm Hg in the nonbevacizumab group and 15.3 ± 8.0 mm Hg in the bevacizumab group, and the median VA was CF in both treatment groups at a mean follow-up of 12 months. Panretinal photocoagulation (PRP) substantially reduced the need for glaucoma surgery (Po0.001) in bevacizumab treated NVG eyes. Conclusions Although bevacizumab delayed the need for glaucoma surgery, PRP was the most important factor that reduced the need for surgery. Vision and IOP in eyes with NVG treated with bevacizumab showed no long-term differences when compared with eyes that were not treated with bevacizumab. Thus, intravitreal bevacizumab serves as an effective temporizing treatment, but is not a replacement for close monitoring and definitive treatment of NVG. PRP remains the treatment modality that affects the course of NVG in terms of decreasing the need for surgery to control IOP.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

Olmos

Sayed

Moraczewski

et al. 2015

Eye

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6][7] Vascular endothelial growth factor (VEGF), which is also a proangiogenic factor, is the best known of these factors. High concentrations of this peptide have been found in the vitreous of patients with macular oedema secondary to several diseases.…”

Section: Introductionmentioning

confidence: 99%

Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema

Garcí-Arumí

Fonollosa

Macia

et al. 2008

Eye

View full text Add to dashboard Cite

Objective In a recent study, we found high levels of erythropoietin (EPO) in patients with diabetic macular oedema (DME), suggesting a role of EPO in the pathogenesis of this condition. To investigate a possible relationship between EPO and other diseases causing macular oedema, we determined vitreous levels of this peptide in patients with macular oedema secondary to retinal vein occlusion (RVO) and compared them with levels in patients with DME and control patients. Methods Vitreous and serum samples were obtained from patients with macular oedema secondary to RVO, DME, epiretinal membrane, and macular hole (controls). EPO was measured by radioimmunoassay. Results No differences were found in median vitreous EPO levels between patients with RVO and controls: RVO, 76 mU/ml (30-806) vs controls, 25 mU/ml (10-75) (P ¼ 0.105). Median EPO concentration was higher in DME patients than in patients with RVO or controls: DME, 430 mU/ml (41-3000) vs RVO, 76 mU/ml (30-806) (Po0.0001) vs controls, 25 mU/ml (10-75) (Po0.0001). Conclusions EPO levels are not elevated in patients with macular oedema secondary to RVO. Patients with DME have high levels of EPO. These results suggest that EPO could be involved in the pathogenesis of diabetic retinopathy, but not in macular oedema secondary to RVO.

show abstract

“…The levels of VEGF and inflammatory cytokines are correlated with severity of retinal ischemia and macular edema (Noma et al, 2006), as well as neovascularization. A close correlation between aqueous VEGF levels and iris neovascularization and vascular permeability in CRVO patients has been found (Boyd et al, 2002).…”

Section: Risk Factors Of Rvomentioning

confidence: 86%

Retinal Vein Occlusion Induced by a MEK Inhibitor - Impact of Oxidative Stress on the Blood-Retinal Barrier

Yang¹,

Huang²

2012

Oxidative Stress and Diseases

View full text Add to dashboard Cite

Correlation of Increased Vascular Endothelial Growth Factor With Neovascularization and Permeability in Ischemic Central Vein Occlusion.

Cited by 50 publications

References 0 publications

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema

Retinal Vein Occlusion Induced by a MEK Inhibitor - Impact of Oxidative Stress on the Blood-Retinal Barrier

Contact Info

Product

Resources

About